Showing results (151-160 of 163) with videos related to
Sort By:
Pageof 17
Journal of Magnetic Resonance Imaging : JMRI|January 28, 2023
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis PatientsAlexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.Brain : a Journal of Neurology|November 14, 2025
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosisAleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, et al.Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.Brain : a Journal of Neurology|December 21, 2024
De-escalating and discontinuing disease-modifying therapies in multiple sclerosisGéraldine Androdias, Jan D Lünemann, Elisabeth Maillart, et al.Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.Neurology|January 2, 2024
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MSAlessandro Cagol, Pascal Benkert, Lester Melie-Garcia, et al.JAMA Neurology|May 16, 2022
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple SclerosisAlessandro Cagol, Sabine Schaedelin, Muhamed Barakovic, et al.Journal of Neuroimmunology|November 18, 2018
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort studyPoul Erik H Jensen, Clemens Warnke, Kathleen Ingenhoven, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 24, 2022
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Anne-Laure Dubessy, Susana Otero-Romero, et al.Pageof 17